Trading Report: The Analysts gives Consensus Recommendation of “Buy” to Hologic Inc. (NASDAQ:HOLX)

The Analysts gives Consensus Recommendation of “Buy” to Hologic Inc. (NASDAQ:HOLX)

Hologic Inc. (NASDAQ:HOLX) has been assigned an average recommendation of “Buy” from the nineteen research firms that are currently covering the stock. Six research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $42.60.

HOLX has been the topic of a number of research analyst reports. Jefferies Group restated a “buy” rating and issued a $42.00 target price on shares of Hologic in a research note on Tuesday, June 21st. Bank of America Corp. reiterated a “buy” rating on shares of Hologic in a research report on Wednesday, June 22nd. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Friday, July 1st. Barclays PLC reiterated a “hold” rating and set a $42.00 price objective on shares of Hologic in a research report on Sunday, July 10th. Finally, Piper Jaffray Cos. set a $40.00 price objective on Hologic and gave the company a “hold” rating in a research report on Monday, July 25th. They noted that the move was a valuation call.

In other news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares in the company, valued at approximately $2,484,180. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.84% of the stock is owned by insiders.

10/05/hologic-inc-nasdaqholx-given-consensus-recommendation-of-buy-by-analysts.html

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Thompson Siegel & Walmsley LLC boosted its position in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the last quarter. Norinchukin Bank The raised its position in Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares during the period. US Bancorp DE raised its position in Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares during the period. Calvert Investment Management Inc. raised its position in Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares during the period. Finally, Raymond James Trust N.A. raised its position in Hologic by 1.1% in the second quarter. Raymond James Trust N.A. now owns 21,989 shares of the company’s stock worth $761,000 after buying an additional 231 shares during the period. Institutional investors own 94.51% of the company’s stock.

Shares of Hologic (NASDAQ:HOLX) traded up 1.07% during midday trading on Wednesday, reaching $39.57. The company’s stock had a trading volume of 1,546,299 shares. The company has a market capitalization of $10.98 billion, a P/E ratio of 43.63 and a beta of 1.00. Hologic has a 12-month low of $31.84 and a 12-month high of $41.66. The company’s 50-day moving average price is $38.33 and its 200 day moving average price is $36.13.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. The business had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 EPS. On average, equities research analysts forecast that Hologic will post $1.94 earnings per share for the current year.

Related posts

Leave a Comment